DENALI THERAPEUTICS INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 15.43 USD | +3.14% |
|
-3.56% | -28.10% |
| Apr. 09 | UBS Adjusts Denali Therapeutics Price Target to $32 From $70, Maintains Buy Rating | MT |
| Apr. 03 | Denali Therapeutics Insider Sold Shares Worth $1,896,250, According to a Recent SEC Filing | MT |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 1,673 | 10,044 | 5,447 | 3,777 | 2,966 | 2,199 | - | - |
| Enterprise Value (EV) 1 | 1,258 | 8,575 | 4,581 | 2,441 | 1,931 | 790.5 | 1,030 | 2,118 |
| P/E ratio | -8.42 x | 133 x | -18.7 x | -10.7 x | -20.2 x | -5.9 x | -5.85 x | -7.19 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 62.7 x | 29.9 x | 112 x | 34.8 x | 8.97 x | 33.4 x | 18.1 x | 8.77 x |
| EV / Revenue | 47.1 x | 25.5 x | 94.1 x | 22.5 x | 5.84 x | 12 x | 8.49 x | 8.45 x |
| EV / EBITDA | -6.13 x | 120 x | -16 x | -7.39 x | -10.7 x | -1.9 x | -2.67 x | -6.07 x |
| EV / FCF | -7.42 x | 20.8 x | -20.8 x | -9.3 x | -5.21 x | -2.22 x | -2.74 x | -8.63 x |
| FCF Yield | -13.5% | 4.82% | -4.8% | -10.8% | -19.2% | -45.1% | -36.5% | -11.6% |
| Price to Book | 4.22 x | 8.78 x | 5.67 x | 3.63 x | 2.86 x | 1.86 x | 2.35 x | 2.81 x |
| Nbr of stocks (in thousands) | 96,031 | 119,918 | 122,126 | 135,814 | 138,197 | 142,540 | - | - |
| Reference price 2 | 17.42 | 83.76 | 44.60 | 27.81 | 21.46 | 15.43 | 15.43 | 15.43 |
| Announcement Date | 2/27/20 | 2/25/21 | 2/28/22 | 2/27/23 | 2/27/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 26.68 | 335.7 | 48.66 | 108.5 | 330.5 | 65.76 | 121.3 | 250.8 |
| EBITDA 1 | -205.2 | 71.25 | -287.2 | -330.4 | -180 | -416.5 | -386.1 | -349 |
| EBIT 1 | -213.2 | 62.72 | -295.8 | -340.7 | -196.7 | -449.2 | -445.7 | -307.8 |
| Operating Margin | -799.1% | 18.69% | -607.78% | -314.16% | -59.51% | -683.15% | -367.45% | -122.76% |
| Earnings before Tax (EBT) 1 | -198 | 71.96 | -291.2 | -326 | -145.2 | -414.6 | -435.5 | -343.8 |
| Net income 1 | -197.6 | 71.14 | -290.6 | -326 | -145.2 | -411.1 | -442 | -337.4 |
| Net margin | -740.74% | 21.19% | -597.15% | -300.56% | -43.94% | -625.18% | -364.34% | -134.54% |
| EPS 2 | -2.070 | 0.6300 | -2.390 | -2.600 | -1.060 | -2.615 | -2.640 | -2.146 |
| Free Cash Flow 1 | -169.5 | 413.1 | -219.9 | -262.5 | -370.9 | -356.1 | -375.9 | -245.5 |
| FCF margin | -635.34% | 123.06% | -451.88% | -242.06% | -112.22% | -541.63% | -309.88% | -97.89% |
| FCF Conversion (EBITDA) | - | 579.74% | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | 580.66% | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Announcement Date | 2/27/20 | 2/25/21 | 2/28/22 | 2/27/23 | 2/27/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 5.285 | 12.51 | 42.14 | 52.48 | 3.559 | 10.28 | 35.14 | 294.1 | 1.267 | - | 13.02 | 12.78 | 12.61 | 12.28 | - |
| EBITDA 1 | -83.41 | -75.03 | -64.42 | -59.34 | -105.3 | -101.3 | -110.8 | 172.8 | - | -130.4 | -111.4 | -100.6 | -108.4 | -90.59 | - |
| EBIT 1 | -85.59 | -77.12 | -66.5 | -61.42 | -107.5 | -105.3 | -120.8 | 170.5 | -113.8 | -132.6 | -117.8 | -110.9 | -113 | -109.6 | - |
| Operating Margin | -1,619.55% | -616.28% | -157.8% | -117.03% | -3,020.12% | -1,024.45% | -343.8% | 57.96% | -8,981.45% | - | -904.84% | -867.57% | -895.64% | -892.63% | - |
| Earnings before Tax (EBT) 1 | -84.59 | -75.84 | -65.22 | -58.77 | -103.3 | -98.68 | -109.8 | 183.4 | -99.35 | -119.4 | -108.8 | -101.5 | -106.1 | -108.9 | - |
| Net income 1 | -84.59 | -75.26 | -65.22 | -58.79 | -103.3 | -98.68 | -109.8 | 183.4 | -99.35 | -119.5 | -106 | -101.4 | -103 | -106.8 | - |
| Net margin | -1,600.53% | -601.41% | -154.77% | -112.03% | -2,902.47% | -959.62% | -312.4% | 62.35% | -7,841.59% | - | -813.86% | -793.36% | -816.14% | -869.69% | - |
| EPS 2 | -0.6900 | -0.6200 | -0.5300 | -0.4800 | -0.8400 | -0.7500 | -0.8000 | 1.300 | -0.7200 | -0.8600 | -0.6973 | -0.6713 | -0.6777 | -0.6590 | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 11/4/21 | 2/28/22 | 5/5/22 | 8/8/22 | 11/3/22 | 2/27/23 | 5/8/23 | 8/8/23 | 11/7/23 | 2/27/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - | - |
| Net Cash position 1 | 415 | 1,470 | 865 | 1,336 | 1,035 | 1,409 | 1,170 | 81.3 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | -169 | 413 | -220 | -263 | -371 | -356 | -376 | -245 |
| ROE (net income / shareholders' equity) | -42% | 9.2% | -27.5% | -32.5% | -14% | -32.4% | -34.5% | -30.2% |
| ROA (Net income/ Total Assets) | -32.5% | 6.59% | -19.3% | -22.8% | -17.6% | -32.9% | -38.6% | -30.9% |
| Assets 1 | 607.6 | 1,079 | 1,504 | 1,432 | 823 | 1,249 | 1,144 | 1,092 |
| Book Value Per Share 2 | 4.130 | 9.550 | 7.870 | 7.670 | 7.500 | 8.290 | 6.560 | 5.490 |
| Cash Flow per Share 2 | - | - | - | -1.950 | -2.610 | 1.180 | -0.2500 | - |
| Capex 1 | 17.9 | 3.1 | 8.5 | 17.8 | 12.9 | 26 | 12.4 | 13.5 |
| Capex / Sales | 67.17% | 0.92% | 17.47% | 16.44% | 3.91% | 39.6% | 10.23% | 5.38% |
| Announcement Date | 2/27/20 | 2/25/21 | 2/28/22 | 2/27/23 | 2/27/24 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
BUY
Number of Analysts
17
Last Close Price
15.43
USD
Average target price
40.27
USD
Spread / Average Target
+160.96%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -28.10% | 2.2B | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.73B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- DNLI Stock
- Financials Denali Therapeutics Inc.
